Sibylla Biotech develops small molecule folding interfering degraders (FIDs) using its proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform, which employs computer simulations and AI to induce the degradation of target proteins. This approach targets proteins involved in various diseases, addressing the need for new therapeutics in multiple therapeutic areas.
Funding
$25.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VBFounders
Product
Problem
Many disease-causing proteins are difficult to target with traditional drugs because they lack well-defined binding pockets or are stabilized by specific folding pathways. This limits the development of effective treatments for a range of diseases.
Solution
Sibylla Biotech develops small molecule folding interfering degraders (FIDs) that induce the degradation of target proteins by interfering with their folding pathways. Their proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform uses computer simulations and AI to identify and develop compounds that destabilize target proteins. This approach enables the targeting of previously undruggable proteins involved in various diseases, offering a new avenue for therapeutic intervention.
Target Audience
Sibylla Biotech's primary customers are pharmaceutical companies seeking novel drug candidates and innovative approaches to target challenging proteins.
Features
- PPI-FIT platform for identifying small molecules that disrupt protein folding.
- Computer simulations to model protein folding pathways at an atomistic level.
- AI-driven analysis to predict and optimize the activity of FIDs.
- Focus on targets involved in central nervous system disorders and other therapeutic areas.
- Development of small molecule degraders with a novel mechanism of action.